Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.42 |
| ▸ | ACLY | P53396 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13515283 | 0.89 | AKR1C3 (0.40) | AKR1C3AKR1C2NR1H2LMNAL3MBTL1 | |
| SCHEMBL10173695 | 0.85 | NR1H2 (0.49) | AKR1C3AKR1C2NR1H2NR1H3 | |
| SCHEMBL18851069 | 0.84 | NR1H2 (0.40) | AKR1C3AKR1C2NR1H2LMNAL3MBTL1 | |
| SCHEMBL18966700 | 0.84 | ESR2 (0.43) | AKR1C3AKR1C2NR1H2MEN1KMT2A | |
| SCHEMBL5436506 | 0.83 | NR1H2 (0.44) | AKR1C3AKR1C2NR1H2NR1H3 | |
| SCHEMBL1621434 | 0.83 | NR1H2 (0.43) | NR1H2NR1H3 | |
| SCHEMBL15040570 | 0.83 | NR1H2 (0.49) | AKR1C3AKR1C2NR1H2NR1H3 | |
| SCHEMBL29955454 | 0.82 | NR1H2 (0.39) | AKR1C3AKR1C2NR1H2LMNAL3MBTL1 | |
| SCHEMBL19013549 | 0.82 | NR1H2 (0.41) | NR1H2ACLYLMNAL3MBTL1MEN1 | |
| SCHEMBL29631993 | 0.82 | NR1H2 (0.41) | NR1H2ACLYLMNAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612075-B2 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | AKR1C3 826/4885AKR1C2 806/4885NR1H2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.